(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Ossification, Heterotopic D009999 2 associated lipids
Pneumonia, Lipid D011017 2 associated lipids
Hemorrhagic Septicemia, Viral D031941 1 associated lipids
Persian Gulf Syndrome D018923 1 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Morel S et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. 2011 Vaccine pmid:21256188
Sarpietro MG et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. 2011 Int J Pharm pmid:21219999
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Manuel O et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. 2011 Clin. Infect. Dis. pmid:21288852
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Precioso AR et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. 2011 Vaccine pmid:21945258
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Vesikari T et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. 2011 N. Engl. J. Med. pmid:21995388
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Jawaid AM et al. Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. 2011 ACS Nano pmid:21770427
Oliaro-Bosso S et al. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. 2011 PLoS ONE pmid:21811565
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Zuccotti GV et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. 2011 Diabet. Med. pmid:21916971
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Weyermann C et al. Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. 2011 J. Forensic Sci. pmid:20707835
Cristiani C et al. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. 2011 Vaccine pmid:21396903
Tabache F et al. Acute polyarthritis after influenza A (H1N1) immunization. 2011 Joint Bone Spine pmid:21444232
Sun Y et al. A reproducible in-vivo model of lymphatic malformation in rats. 2011 J. Comp. Pathol. pmid:21419420
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876
Banzhoff A et al. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. 2011 Hum Vaccin pmid:21422814
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Dorea JG Safety of thimerosal in vaccines: for whom and how many doses? 2011 Mar-Apr Therapie pmid:23189333
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Vesikari T et al. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. 2012 Hum Vaccin Immunother pmid:22777094
Bencharitiwong R et al. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. 2012 Hum Vaccin Immunother pmid:22777093
Gasparini R et al. Aflunov(®): a prepandemic influenza vaccine. 2012 Expert Rev Vaccines pmid:22309663
Spanova M et al. Influence of squalene on lipid particle/droplet and membrane organization in the yeast Saccharomyces cerevisiae. 2012 Biochim. Biophys. Acta pmid:22342273
Palma P et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. 2012 Biologicals pmid:22261282
Heikkinen T et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. 2012 Am. J. Obstet. Gynecol. pmid:22939717
Mannino S et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. 2012 Am. J. Epidemiol. pmid:22940713
Klucker MF et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. 2012 J Pharm Sci pmid:22941944
Cosco D et al. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases. 2012 Int J Nanomedicine pmid:22679366
O'Hagan DT et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. 2012 Vaccine pmid:22682289
Lokvam J and Fine PV An oxidized squalene derivative from Protium subserratum Engl. (Engl.) growing in Peru. 2012 Molecules pmid:22706374
Yu S et al. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. 2012 Vaccine pmid:22709954
Peric M et al. Electron paramagnetic resonance line shifts and line shape changes due to heisenberg spin exchange and dipole-dipole interactions of nitroxide free radicals in liquids 8. Further experimental and theoretical efforts to separate the effects of the two interactions. 2012 J Phys Chem A pmid:22288424
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Liu YT et al. Protein engineering of Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase into parkeol synthase. 2012 Org. Lett. pmid:23043506
Ta MT et al. Accumulation of squalene is associated with the clustering of lipid droplets. 2012 FEBS J. pmid:23013491
Nielsen AB et al. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. 2012 Vaccine pmid:23036498